Top Abstract Spotlight: Menin Inhibitors are a Game Changer for the Treatment of Patients with Newly Diagnosed AML 

In this interview, Dr. Wei-Ying Jen, Anderson Cancer Center, emphasises that the combination of revumenib, decitabine/cedazuridine, and venetoclax produced high remission and MRD negativity rates in genomically defined AML subtypes traditionally associated with poor prognosis.